David Wallace
Deputy Editor
Ireland
+11 year(s) experience
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year.
Topic biopharmaceutical
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
The pharmaceutical selling model will be modified even after the immediate COVID-19 pandemic crisis abates, the consulting firm ZS Associates predicts, citing new research.
Topic Coronavirus
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
A Phase III trial testing Kevzara in hospitalized COVID-19 patients will continue only with the high dose in more advanced critical patients after the low-dose was unsuccessful.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Sales of the triglyceride-lowering medicine soared to $112.4m in the third quarter even before a label expansion that depends on the outcome of a vital US FDA advisory committee meeting on 14 November.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Drug makers remained front and center during the Senate Finance Committee's third hearing on drug pricing, even though leaders from five pharmacy benefit managers were testifying.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
CEO Craig Wheeler talked toScripabout the challenging biosimilar market dynamics and the company's decision to end most biosimilar drug development. The path to value creation in biosimilars is not clear, he said.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
CEO Alex Gorsky highlighted growing public concern over US drug costs during J&J's Q4 earnings call, pressing for more transparency and value-based health care. The company's net drug prices declined more than 6% in 2018, he added.
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.
Topic Policy and regulation
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Investors weren't wildy impressed by the data at ASCO this year, but for pharma, the meeting felt like a renewal, a re-commitment to getting it right. It was more a year of refinement as industry digests the advances that have been made, the big mistakes, and pivots toward where to go next.
Topic cancer
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market.
Topic business-strategies
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
From "getting away with murder" to "rip-off drug prices," pharma had its share of face-offs with President Trump in 2017
Topic policy-and-regulation
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Shire filed a lawsuit against Allergan, claiming that Allergan's exclusive contracting tactics for Restasis under Medicare Part D have blocked Xiidra from the market.
Topic Reimbursement
Scrip: 世界の医療用医薬品&製薬産業に関するニュース
Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits.
Scrip: 世界の医療用医薬品&製薬産...
24 Feb 2021
Scrip: 世界の医療用医薬品&製薬産...
11 Feb 2021
Scrip: 世界の医療用医薬品&製薬産...
11 Feb 2021
Scrip: 世界の医療用医薬品&製薬産...
03 Feb 2021
Scrip: 世界の医療用医薬品&製薬産...
02 Feb 2021
Scrip: 世界の医療用医薬品&製薬産...
01 Feb 2021
Scrip: 世界の医療用医薬品&製薬産...
28 Jan 2021
Scrip: 世界の医療用医薬品&製薬産...
25 Jan 2021
Scrip: 世界の医療用医薬品&製薬産...
21 Jan 2021
Scrip: 世界の医療用医薬品&製薬産...
13 Jan 2021
Pink Sheet: 世界の薬事規制と...
11 Dec 2020
Scrip: 世界の医療用医薬品&製薬産...
03 Dec 2020
Scrip: 世界の医療用医薬品&製薬産...
30 Nov 2020
Scrip: 世界の医療用医薬品&製薬産...
17 Nov 2020
In Vivo: 医療用医薬品・医療機器...
09 Nov 2020